Peptides by condition · Muscles, bones, joints and skin

Peptides studied for erythropoietic protoporphyria (EPP)

Checked against our study pages and the FDA labelsPublished by PepVault

Our library holds 3 study pages on erythropoietic protoporphyria (EPP): 3 in people (1 of them a meta-analysis or randomized trial). They studied one compound, Melanotan I.

What the research on erythropoietic protoporphyria (EPP) looks like

Erythropoietic protoporphyria (EPP) is a rare inherited disease in which a substance called protoporphyrin builds up in the blood and skin. Sunlight, even through a window, then sets off burning pain in the skin, so people with EPP learn to stay out of the light. The peptide studied here is afamelanotide, a copy of the hormone that darkens skin, given as a small implant under the skin. Symptoms usually begin in early childhood, and the pain often comes with little visible redness or swelling, so many people wait years for a diagnosis.

These studies measure how long people can stay in daylight without pain, how many painful light reactions they have, and their quality of life on a questionnaire written for EPP. In the trials, patients kept a daily diary of their time in direct sunlight and of each light reaction, and rated how painful each one was.

Two of the three studies followed patients who were already on the drug, with no comparison group, and people who stay on a drug are often the ones it suits, so the placebo-controlled trials carry the most weight. Time in the light was logged by the patients themselves, and the weather and season change how much daylight there is to spend, which is why trials compare groups over the same months.

Our study pages on erythropoietic protoporphyria (EPP) by design: Trials in people 1, Other in people 2, Animals 0, Cells 0, of 3.Trials in people1Other in people2Animals0Cells0
How many of the 3 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.
A smiling man in a grey training top on a sofa with a foam roller beside him, his phone in his hands

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The 3 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

  1. Melanotan I

    3 in people

    For erythropoietic protoporphyria (EPP), 3 of our study pages are filed under Melanotan I: 1 randomized trial and 2 observational studies in people. The largest in people enrolled 121 people and was published in 2023. They were published from 2015 to 2023, in N Engl J Med, J Dermatol and J Drugs Dermatol.

    FDA-approved, with a use tied to erythropoietic protoporphyria (EPP) on its label: Scenesse (implant) for more pain-free time in light for adults who have had light reactions from erythropoietic protoporphyria (EPP), a rare inherited disease.

Side by side

For the compound on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

CompoundIn peopleAnimals or cellsLargest in peopleFDA
Melanotan I30121Approved, a use tied to it

What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

Questions

Which peptides have been studied for erythropoietic protoporphyria (EPP)?

Our 3 study pages on erythropoietic protoporphyria (EPP) are all filed under one compound, Melanotan I.

Have any been tested in people with erythropoietic protoporphyria (EPP)?

Yes: all 3 were in people, 1 of them a meta-analysis or randomized trial (Melanotan I). The largest enrolled 121 people: “Melanotan I: EPP quality-of-life score rose from 44% to 75%” (2023).

Is any peptide FDA-approved for erythropoietic protoporphyria (EPP)?

Yes, with a use tied to erythropoietic protoporphyria (EPP) on their FDA labels: Melanotan I as Scenesse. Every compound here is.

How large were the studies in people on erythropoietic protoporphyria (EPP)?

Of the 3 in people, 1 gives its size on our pages: 1 had 100 to 999. The largest, an observational study from 2023, enrolled 121.

What is the newest study on erythropoietic protoporphyria (EPP) here?

Of our study pages on erythropoietic protoporphyria (EPP), the newest is “Melanotan I: EPP quality-of-life score rose from 44% to 75%”, an observational study in people published in 2023.

How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

Track it in the app

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo